Tezacaftor: Difference between revisions

Tezacaftor
	File:Tezacaftor.svg
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Latest revision as of 01:17, 20 February 2025

A medication used in the treatment of cystic fibrosis

Tezacaftor is a medication used in the management of cystic fibrosis, a genetic disorder that affects the lungs and other organs. It is often used in combination with other drugs to improve the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, which is defective in individuals with cystic fibrosis.

Mechanism of Action[edit]

Tezacaftor works by correcting the folding of the CFTR protein, allowing it to reach the cell surface where it can function properly. This action helps to improve the movement of chloride ions across cell membranes, which is impaired in cystic fibrosis patients. By enhancing CFTR function, tezacaftor helps to reduce the symptoms and complications associated with the disease.

Clinical Use[edit]

Tezacaftor is typically used in combination with other CFTR modulators, such as ivacaftor, to enhance its therapeutic effects. The combination therapy is indicated for patients with specific mutations in the CFTR gene that are responsive to this treatment approach. The use of tezacaftor in combination with ivacaftor has been shown to improve lung function and reduce pulmonary exacerbations in patients with cystic fibrosis.

Side Effects[edit]

Common side effects of tezacaftor include headache, nausea, and dizziness. Some patients may also experience respiratory symptoms such as cough or nasal congestion. It is important for patients to be monitored for any adverse reactions during treatment.

Administration[edit]

Tezacaftor is administered orally, usually in the form of a tablet. The dosage and frequency of administration depend on the specific combination therapy and the patient's individual response to treatment.

Related pages[edit]

Tezacaftor

Tezacaftor

@@ Line 1: / Line 1: @@
-'''Tezacaftor''' is a medication used in combination with [[Ivacaftor]] for the treatment of [[Cystic Fibrosis]] (CF) in certain individuals. It is specifically designed for patients who have at least one F508del mutation in the [[CFTR]] gene, which is the most common genetic cause of the disease. Tezacaftor works by improving the function of the CFTR protein, which is defective in people with cystic fibrosis. By enhancing the protein's activity, it helps to manage the symptoms and complications of the disease.
+{{Short description|A medication used in the treatment of cystic fibrosis}}
+{{Drugbox
+| image = Tezacaftor.svg
+| image2 =
+}}
-== Mechanism of Action ==
+'''Tezacaftor''' is a medication used in the management of [[cystic fibrosis]], a genetic disorder that affects the lungs and other organs. It is often used in combination with other drugs to improve the function of the [[cystic fibrosis transmembrane conductance regulator]] (CFTR) protein, which is defective in individuals with cystic fibrosis.
-Tezacaftor functions as a CFTR corrector. It assists in the proper folding and trafficking of the CFTR protein to the cell surface. Once at the surface, the CFTR protein can perform its normal function of regulating salt and water transport across cell membranes. This action helps to thin the thick mucus that is characteristic of cystic fibrosis, thereby improving lung function and reducing the risk of infections.
-== Usage ==
+==Mechanism of Action==
-Tezacaftor is used in combination therapy with Ivacaftor, another medication that enhances the activity of the CFTR protein at the cell surface. The combination is approved for use in patients aged 6 years and older with cystic fibrosis who have specific mutations in the CFTR gene. The treatment regimen involves taking Tezacaftor in the morning and Ivacaftor in the evening.
+Tezacaftor works by correcting the folding of the CFTR protein, allowing it to reach the cell surface where it can function properly. This action helps to improve the movement of chloride ions across cell membranes, which is impaired in cystic fibrosis patients. By enhancing CFTR function, tezacaftor helps to reduce the symptoms and complications associated with the disease.
-== Clinical Trials ==
+==Clinical Use==
-Clinical trials have demonstrated that the combination of Tezacaftor and Ivacaftor significantly improves lung function in individuals with cystic fibrosis who have the F508del mutation. The treatment has also been associated with a reduction in pulmonary exacerbations and an improvement in the quality of life for patients.
+Tezacaftor is typically used in combination with other CFTR modulators, such as [[ivacaftor]], to enhance its therapeutic effects. The combination therapy is indicated for patients with specific mutations in the CFTR gene that are responsive to this treatment approach. The use of tezacaftor in combination with ivacaftor has been shown to improve lung function and reduce pulmonary exacerbations in patients with cystic fibrosis.
-== Side Effects ==
+==Side Effects==
-The most common side effects of Tezacaftor in combination with Ivacaftor include headache, nasal congestion, and dizziness. These side effects are generally mild to moderate in severity. However, patients are advised to report any adverse reactions to their healthcare provider.
+Common side effects of tezacaftor include headache, nausea, and dizziness. Some patients may also experience respiratory symptoms such as cough or nasal congestion. It is important for patients to be monitored for any adverse reactions during treatment.
-== Approval ==
+==Administration==
-The combination of Tezacaftor and Ivacaftor was approved by the [[Food and Drug Administration]] (FDA) in the United States and by the European Medicines Agency (EMA) in the European Union. The approval was based on the positive outcomes from clinical trials demonstrating the efficacy and safety of the combination therapy.
+Tezacaftor is administered orally, usually in the form of a tablet. The dosage and frequency of administration depend on the specific combination therapy and the patient's individual response to treatment.
-== Conclusion ==
+==Related pages==
-Tezacaftor, in combination with Ivacaftor, represents a significant advancement in the treatment of cystic fibrosis for patients with specific genetic mutations. By targeting the underlying cause of the disease, this therapy offers hope for improved lung function, reduced complications, and a better quality of life for individuals affected by cystic fibrosis.
+* [[Cystic fibrosis]]
+* [[Ivacaftor]]
+* [[CFTR modulator]]
-[[Category:Pharmacology]]
+[[Category:Cystic fibrosis treatments]]
-[[Category:Cystic Fibrosis]]
+[[Category:Drugs]]
-{{pharmacology-stub}}
+<gallery>
+File:Tezacaftor.svg|Tezacaftor
+</gallery>